Mehrabi Fatemeh, Safdari Ali, Moslemi Azam, Salehi Mehdi, Agharazi Ali, Rezvanfar Mohammad Reza
Department of Nursing, Nursing and Midwifery Faculty, Arak University of Medical Sciences, Arak, Iran.
Department of Nursing, Malayer School of Medical Sciences, Chronic Diseases (Home Care) Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Contemp Clin Trials Commun. 2024 Nov 24;43:101401. doi: 10.1016/j.conctc.2024.101401. eCollection 2025 Feb.
Type 2 Diabetes is a common and chronic metabolic disease. Complementary and alternative medicine can provide a suitable option for demands for new treatments. Therefore, the present study aimed to investigate the effect of Persian medicine on the glycemic status of patients with Type 2 Diabetes.
This randomized, controlled, and triple-blind trial study was conducted from November 2021 to August 2022 on 102 diabetic patients referred to the diabetes clinic in Iran. In this regard, patients with inclusion criteria were randomly divided into three groups (n = 34), (n = 34), and the control group (n = 34). The control group received a placebo of medicinal salt, light calcium carbonate, lactose, and carboxymethyl cellulose. In contrast, the treatment groups received 25 g of drug powder (in 250 cc of lukewarm water) on an empty stomach for 8 consecutive weeks. Patients' fasting blood sugar (FBS) levels and HbA1c were measured at the beginning and end of the intervention. Data were analyzed using SPSS 23, employing paired t-tests, ANOVA, and chi-square tests for comparison between groups.
Data analysis was conducted on 90 patients with Type 2 Diabetes. The findings revealed a significant reduction in fasting blood sugar levels post-intervention in the Ma'aljobon Aftimouni group (134.27 ± 21.79 vs. 152.3 ± 31.37, mean difference 18.03 ± 5.63, 95 % CI: 6.53 to 29.53, p = 0.003). Additionally, a significant difference in HbA1c values was observed post-intervention in both the Ma'aljobon Aftimouni group (7.88 ± 0.77 vs. 8.09 ± 0.73, mean difference 0.21 ± 0.09, 95 % CI: 0.03 to 0.39, p = 0.031) and the Ma'aljobon without Aftimoun group (7.97 ± 0.84 vs. 8.25 ± 0.78, mean difference 0.28 ± 0.08, 95 % CI: 0.11 to 0.45, p = 0.002).
The findings showed that daily consumption of Ma'aljobon supplements on an empty stomach before breakfast may have a beneficial effect on the glycemic indices of patients. However, further studies seem to be necessary in this regard.
2型糖尿病是一种常见的慢性代谢性疾病。补充和替代医学可为新治疗方法的需求提供合适选择。因此，本研究旨在探讨波斯医学对2型糖尿病患者血糖状况的影响。
本随机、对照、三盲试验研究于2021年11月至2022年8月对转诊至伊朗糖尿病诊所的102例糖尿病患者进行。在此方面，符合纳入标准的患者被随机分为三组（n = 34）、（n = 34）和对照组（n = 34）。对照组接受药用盐、轻质碳酸钙、乳糖和羧甲基纤维素的安慰剂。相比之下，治疗组连续8周空腹服用25克药粉（溶于250毫升温水中）。在干预开始和结束时测量患者的空腹血糖（FBS）水平和糖化血红蛋白（HbA1c）。使用SPSS 23进行数据分析，采用配对t检验、方差分析和卡方检验进行组间比较。
对90例2型糖尿病患者进行了数据分析。结果显示，Ma'aljobon Aftimouni组干预后空腹血糖水平显著降低（134.27±21.79对152.3±31.37，平均差值18.03±5.63，95%CI：6.53至29.53，p = 0.003）。此外，Ma'aljobon Aftimouni组（7.88±0.77对8.09±0.73，平均差值0.21±0.09，95%CI：0.03至0.39，p = 0.031）和无Aftimoun的Ma'aljobon组（7.97±0.84对8.25±0.78，平均差值0.28±0.08，95%CI：0.11至0.45，p = 0.002）干预后糖化血红蛋白值均有显著差异。
研究结果表明，早餐前空腹每日服用Ma'aljobon补充剂可能对患者的血糖指标有有益影响。然而，在这方面似乎有必要进行进一步研究。
